e-learning
resources
Amsterdam 2011
Monday, 26.09.2011
Smoking-related diseases and smoking cessation
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Predicted impact of access to varenicline on abstinence simulating multiple quit attempts over smokers‘ lifetimes
R. J. Willke, D. Getsios, J. P. Marton, N. Revankar, K. H. Zou, J. Xenakis (New York, Lexington, United States Of America)
Source:
Annual Congress 2011 - Smoking-related diseases and smoking cessation
Session:
Smoking-related diseases and smoking cessation
Session type:
Poster Discussion
Number:
1796
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. J. Willke, D. Getsios, J. P. Marton, N. Revankar, K. H. Zou, J. Xenakis (New York, Lexington, United States Of America). Predicted impact of access to varenicline on abstinence simulating multiple quit attempts over smokers‘ lifetimes. Eur Respir J 2011; 38: Suppl. 55, 1796
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Related content which might interest you:
Predicted health and economic benefits of smoking cessation incorporating multiple quit attempts over a lifetime
Source: Annual Congress 2011 - Smoking cessation science
Year: 2011
Repeated antismoking counseling increases quit rate: relation to motivation and nicotine dependence
Source: Eur Respir J 2005; 26: Suppl. 49, 489s
Year: 2005
Improvement of quit smoking rate by combining varenicline and nicotine replacement therapy
Source: Annual Congress 2009 - Smoking cessation
Year: 2009
Couples of significant others (COSO) in a joint effort to quit smoking are more successful in achieving and maintaining abstinence
Source: Annual Congress 2012 - Tobacco cessation
Year: 2012
Most users quit e-cigarettes without succeeding to quit smoking
Source: Virtual Congress 2021 – Tobacco and nicotine research during the pandemic
Year: 2021
The cost-effectiveness of smoking cessation interventions. Accounting for medical costs in longer life expectancies
Source: Annual Congress 2006 - How to treat tobacco smokers
Year: 2006
Evaluation of the relationship between intention to quit and not smoking at home
Source: Annual Congress 2012 - Tobacco comorbidity
Year: 2012
The success rate of a smoking cessation programme in patients attempted to quit smoking
Source: Eur Respir J 2002; 20: Suppl. 38, 133s
Year: 2002
Causes of quitting treatment with varenicline in a smoking cessation clinic
Source: Annual Congress 2009 - Epidemiology of smoking and smoking cessation
Year: 2009
Are electronic cigarettes the real solution to quit smoking?
Source: Virtual Congress 2021 – CCC Interstitial lung diseases
Year: 2021
Effect of local program to quit smoking
Source: Eur Respir J 2005; 26: Suppl. 49, 391s
Year: 2005
The comparative effectiveness of smoking cessation drugs on prolonged abstinence – a network meta-analysis
Source: Annual Congress 2009 - Smoking cessation
Year: 2009
Electronic cigarettes for smoking cessation: an opportunity to readdress smoking cessation treatment
Source: Eur Respir J, 56 (4) 2000098; 10.1183/13993003.00098-2020
Year: 2020
Clinical and pathological determinants of abstinence rate in smoking cessation with varenicline
Source: Annual Congress 2010 - Smoking cessation interventions
Year: 2010
Harmful effects of smoking: are they adequate reasoning for smokers to quit it?
Source: Annual Congress 2009 - Smoking cessation
Year: 2009
Comparison of efficiacy and success of hypnotherapy and medical drugs to quit smoking. First 6 months results
Source: Annual Congress 2009 - Epidemiology of smoking and smoking cessation
Year: 2009
Occurrence, health impact and motivation to quit smoking among young people and effectiveness of tobacco control programs
Source: Annual Congress 2012 - Tobacco and shisha exposure in children and adolescents
Year: 2012
The cost of smoking as a reason to quit: results from an open survey
Source: Eur Respir J 2004; 24: Suppl. 48, 155s
Year: 2004
The respiratory health benefits of quitting cannabis use
Source: Eur Respir J 2015; 46: 1-4
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept